Thymosin Alpha-1: Immune Modulation, Dosage, and Protocols
Quick facts
- Full name
- Thymosin Alpha-1 (TA-1, Thymalfasin; brand: Zadaxin)
- Structure
- 28-amino acid peptide; N-terminally acetylated; derived from thymosin fraction 5
- Primary pathway
- TLR2/4 and TLR9 agonism; dendritic cell maturation; Th1/Th2 immune balance regulation
- Main research uses
- Immune optimization, chronic viral infection support, oncology adjuvant, post-viral recovery, aging immune system
- Route
- Subcutaneous injection
- Typical dose
- 1.5-1.6 mg twice weekly; some longevity protocols use 1.5 mg once weekly as maintenance
- Half-life
- Approximately 2 hours; immune effects are long-lasting through downstream cell programming
- Clinical approval
- Approved in Italy, China, and other countries for HBV, HCV, melanoma adjuvant; not FDA-approved
- Evidence quality
- Highest among commonly used research peptides: multiple RCTs in hepatitis and oncology
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a naturally occurring peptide first isolated in 1977 by Allan Goldstein's lab at George Washington University from thymosin fraction 5, a thymic extract. The thymus gland produces multiple thymosin proteins responsible for T-cell maturation and immune system calibration. TA-1 turned out to be one of the most biologically active components in that extract.
The commercial form, Thymalfasin (brand name Zadaxin, manufactured by SciClone Pharmaceuticals), is a synthetic version of the identical 28-amino acid sequence. It is N-terminally acetylated, which is the native post-translational modification and is required for full biological activity. Generic TA-1 research compounds follow the same structure.
What distinguishes TA-1 from most research peptides is its evidence base. Unlike compounds studied primarily in rodents or small case series, TA-1 has been through multiple Phase II and Phase III randomized controlled trials, primarily in hepatitis B, hepatitis C, and oncology contexts. This clinical history provides a dosing reference, safety record, and pharmacokinetic profile that most research peptides lack entirely.
Mechanism of Action
TA-1 acts through several interconnected immune pathways:
Toll-Like Receptor Signaling
TA-1 engages toll-like receptors 2, 4, and 9, which are pattern recognition receptors on innate immune cells (macrophages, dendritic cells, monocytes). TLR activation by TA-1 triggers NF-kB and IRF3 signaling cascades, which drive expression of type I interferons (IFN-alpha, IFN-beta) and pro-inflammatory cytokines that activate downstream adaptive immunity. This is the primary mechanism by which TA-1 enhances antiviral and antitumor responses.
Dendritic Cell Maturation
Dendritic cells (DCs) are the bridge between innate and adaptive immunity. They sample tissue for antigens and then migrate to lymph nodes to present those antigens to T cells. Immature DCs are poor antigen presenters. TA-1 drives DC maturation, enhancing expression of MHC class II molecules, co-stimulatory molecules (CD80, CD86), and cytokine secretion capacity. The net effect is more efficient antigen presentation and stronger T-cell priming.
Th1/Th2 Balance
TA-1 shifts the cytokine environment toward a Th1-dominant pattern (IFN-gamma, IL-2, IL-12), which is the profile associated with effective antiviral and antitumor responses. Conditions characterized by immune exhaustion, chronic infection, or age-related immune dysfunction (immunosenescence) tend to show Th2 skewing and impaired Th1 responses. TA-1 restores this balance in multiple preclinical and clinical models.
NK Cell Activation
Natural killer cells are the immune system's rapid-response cytotoxic cells. They kill virally infected and tumor cells without requiring prior antigen sensitization. NK cell activity declines with age and is often depressed in chronic viral infection. TA-1 restores and enhances NK cell cytotoxic activity, which is relevant to both chronic infection management and cancer immunosurveillance.
Clinical Evidence Summary
TA-1 has a more substantial clinical evidence base than virtually any other peptide commonly discussed in research communities. Key trials:
| Indication | Trial Type | Key Finding | Evidence |
|---|---|---|---|
| Hepatitis B | Phase III RCT (Cheng et al., multiple) | Improved HBeAg seroconversion vs control; greatest benefit in active immune responders | Strong |
| Hepatitis C | Phase II/III RCTs | Improved virologic response when combined with interferon vs interferon alone | Strong |
| Melanoma vaccine adjuvant | Phase III RCT (EORTC) | Improved relapse-free survival when combined with Decarbazine; approved in Italy | Strong |
| Sepsis | Phase III RCT (China, multiple) | Reduced 28-day mortality in severe sepsis patients with immunoparalysis (low HLA-DR monocytes) | Moderate |
| COVID-19 (acute) | Retrospective / pilot RCTs (China 2020) | Faster lymphocyte recovery; reduced progression in moderate disease; large RCT results pending | Moderate |
| Post-viral fatigue / Long COVID | Case series / pilot studies | Reported improvements in NK cell activity and fatigue markers; no large RCT data | Limited |
| Immune optimization (healthy) | No RCT data | Extrapolated from clinical populations; no healthy volunteer efficacy trials | Limited |
The evidence is strongest for defined immune-deficient states: chronic viral infection, immunoparalysis in critical illness, and cancer adjuvant settings. The extrapolation to healthy aging or general immune optimization is biologically plausible but lacks direct trial support. Researchers using TA-1 for longevity and immune optimization are working by analogy from the clinical data rather than from specific trials in that population.
Dosage Protocols
Clinical trials used 1.6 mg twice weekly as the standard dose for most indications, administered subcutaneously. Research and longevity protocols largely follow this benchmark.
| Protocol | Dose | Frequency | Duration | Context |
|---|---|---|---|---|
| Clinical (HBV/HCV) | 1.6 mg | Twice weekly | 6 months | Formal trial protocol; regulatory approval basis |
| Research standard | 1.5 mg | Twice weekly | 4-12 weeks | Mirrors clinical dosing; most commonly reported |
| Longevity maintenance | 1.5 mg | Once weekly | Ongoing or cycled | Commonly used after an initial 4-week loading phase |
| Acute immune support | 1.6 mg | Every other day x 2 weeks, then twice weekly | 4-6 weeks | Post-viral or acute immune depression; modeled on sepsis trials |
Injections should be separated by at least 48 hours to allow the immune activation response to complete before restimulation. TA-1 does not require fasting. Subcutaneous injection into the abdomen or thigh is standard; see the injection guide for technique.
Reconstitution
TA-1 is typically supplied as lyophilized powder in 1.6 mg vials (matching the clinical dose). Reconstitute with sterile or bacteriostatic water. Adding 1 mL of BAC water produces a 1.6 mg/mL solution, so each 1 mL draw is one full dose. Store at 2-8°C after reconstitution; lyophilized powder is stable at room temperature for short periods.
Safety Profile
TA-1 has one of the cleanest safety records in the peptide research space. Across clinical trials totaling thousands of patient-years of exposure:
- No organ toxicity reported at therapeutic doses
- No significant drug interactions established
- No carcinogenicity or mutagenicity findings in preclinical work
- Used safely in immunocompromised patients (cancer, HIV, elderly) at standard doses
Common but mild effects that resolve without intervention:
- First-injection flu-like symptoms (low-grade fever, mild fatigue, occasional headache) in roughly 10-15% of users. This is attributed to the initial immune activation response and typically does not recur.
- Local injection site reactions (redness, mild swelling) consistent with subcutaneous injections in general
No dose-dependent toxicity has been established up to 10x the therapeutic dose in animal models. The therapeutic index is considered very wide.
Applications in Longevity Research
Immunosenescence, the age-related decline in immune function, is now recognized as a driver of many aging pathologies rather than just a consequence. Older adults show reduced NK cell cytotoxicity, impaired dendritic cell function, thymic involution (reduced T-cell output), and a shift toward a low-grade chronic inflammatory state called inflammaging. TA-1 addresses several of these specifically.
Its natural pairing in longevity protocols is with Epithalon, a tetrapeptide that targets telomerase activation and circadian/melatonin axis regulation. Epithalon works through epigenetic and telomere-length mechanisms; TA-1 works through active immune function restoration. The two compounds address complementary aging pathways without mechanism overlap, which is the rationale for combining them. A typical longevity cycle runs Epithalon at 5-10 mg daily for 10-20 days, with TA-1 at 1.5 mg twice weekly running concurrently or in sequence.
TA-1 vs Other Immune Peptides
Thymosin Alpha-1 vs BPC-157
These peptides address different immune aspects. BPC-157 (body protection compound) works primarily at the tissue repair and mucosal level: gut lining integrity, angiogenesis, growth factor upregulation. Its immune relevance is mostly local and tissue-specific. TA-1 operates at the systemic immune level: circulating lymphocytes, NK cells, dendritic cells. A researcher dealing with gut dysbiosis and systemic immune dysfunction would use both, not choose between them.
Thymosin Alpha-1 vs Thymosin Beta-4 (TB-500)
Thymosin Alpha and Beta are different protein families despite sharing "thymosin" in the name. TB-500 (derived from Thymosin Beta-4) is primarily a tissue repair peptide: actin-binding, angiogenesis, wound healing. TA-1 is a systemic immune modulator. Despite the naming similarity they have essentially no mechanism overlap. TB-500 is the repair tool; TA-1 is the immune calibration tool.
Stacking Protocols
TA-1 + Epithalon (Longevity Stack)
The most commonly cited longevity pairing. Run a 10-20 day Epithalon course (5-10 mg/day SC) with TA-1 at 1.5 mg twice weekly for 4-6 weeks. The combination addresses telomere maintenance, circadian regulation, NK cell function, and T-cell responsiveness. Some longevity researchers extend TA-1 to monthly maintenance (1.5 mg once weekly) between Epithalon cycles.
TA-1 + BPC-157 (Post-Viral or Post-Infection)
For post-viral recovery protocols, combining TA-1's systemic immune restoration with BPC-157's gut-immune axis support is the most logical pairing. BPC-157 at 200-400 mcg/day SC addresses intestinal permeability and local gut inflammation that often persists post-viral. TA-1 at 1.5 mg twice weekly drives NK cell recovery and Th1 cytokine restoration. The two can be administered on the same days in separate injections.
TA-1 as Vaccine Adjuvant (Research Context)
The clinical trial data on TA-1 as an adjuvant for cancer vaccines and hepatitis vaccines is well-established. Researchers studying vaccine response or immune priming sometimes incorporate TA-1 in the weeks surrounding vaccine administration based on this clinical literature, though this is extrapolation beyond approved indications.
Frequently Asked Questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 (TA-1, Thymalfasin) is a 28-amino acid peptide originally isolated from thymosin fraction 5 in the thymus gland. It modulates innate and adaptive immunity primarily through toll-like receptor signaling and dendritic cell maturation. It is sold under the brand name Zadaxin and is approved in some countries for hepatitis B, hepatitis C, and as a cancer vaccine adjuvant.
What is the standard Thymosin Alpha-1 dosage?
The dose validated in formal clinical trials is 1.6 mg twice weekly by subcutaneous injection, separated by at least 48 hours. Research and longevity protocols typically use 1.5 mg twice weekly as the equivalent. Protocols for immune optimization run 4-12 weeks. Some researchers use a lower maintenance dose (1.5 mg once weekly) after an initial loading phase.
Is Thymosin Alpha-1 safe?
TA-1 has one of the most favorable safety profiles among all research peptides. Clinical trials involving thousands of patients showed minimal adverse events. The most common first-use effect is a transient mild flu-like feeling attributed to initial immune activation. No organ toxicity, serious adverse events, or significant drug interactions have been established in the published literature.
How does Thymosin Alpha-1 differ from other immune peptides like BPC-157?
The mechanisms are quite different. TA-1 works through systemic immune modulation: TLR signaling, dendritic cell maturation, NK cell activation, and Th1/Th2 balance. BPC-157 works primarily at the local tissue level: angiogenesis, growth factor upregulation, mucosal healing, and gut-brain axis signaling. They address different systems and stack well precisely because they do not overlap.
Can Thymosin Alpha-1 be used for Long COVID or post-viral fatigue?
Post-viral research use has increased substantially since 2020. The rationale is TA-1's documented ability to restore depressed NK cell activity and support viral clearance. A small number of case series and pilot trials have reported improvements in post-COVID immune markers and fatigue scores. The evidence is preliminary and not from large RCTs. Researchers typically reference the hepatitis trial dosing of 1.6 mg twice weekly for 8-12 weeks as a starting point.